real world evidence comes into play when clinical trials cannot really account for the entire patient population of a particular disease. patients suffering from comorbidities or belonging to a distant geographic region or age limit who did not participate in any clinical trial may not respond to the treatment in question as expected. rwe provides answers to these problems and also to analyze effects of drugs over a longer period of time. pharmaceutical companies and health insurance payers study rwe to understand patient pathways to deliver appropriate care for appropriate individuals and to minimize their own financial risk by investing on drugs that work for patients.